A Latent Pharmacokinetic Time Profile to Model Dose-Response Survival Data

By Jacobs Tom  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 4, 2010-07 ,pp. : 759-767

Taylor & Francis Ltd

Access to resources Recommend Favorite

Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models

By Xu Xu  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 38, Iss. 4, 2011-08 ,pp. : 423-432

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments

By Locati Laura D.   Licitra Lisa   Agate Laura   Ou Sai-Hong I.   Boucher Andree   Jarzab Barbara   Qin Shukui   Kane Madeleine A.   Wirth Lori J.   Chen Connie   Kim Sinil   Ingrosso Antonella   Pithavala Yazdi K.   Bycott Paul   Cohen Ezra E. W.  

Cancer, Vol. 120, Iss. 17, 2014-09 ,pp. : 2694-2703

Blackwell Publishing

Access to resources Recommend Favorite

Estimating Area Under the Curve and Relative Exposure in a Pharmacokinetic Study with Data Below Quantification Limit

By Fang Liang  

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 1, 2011-01 ,pp. : 66-76

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacokinetic Study of Esomeprazole in the Elderly

By Hasselgren G.  

Clinical Pharmacokinetics, Vol. 40, Iss. 2, 2001-01 ,pp. : 145-150

Adis International

Access to resources Recommend Favorite